XerisDD - A Community of Due Diligence
The place to share knowledge & better understand Xeris BioPharma
What Lies Ahead For Xeris Biopharma In 2022
Jan. 1 PDUFA for Recorlev, Merck collaboration, Levothyroxine Phase 1, EIH Phase 2, and growing sales for Gvoke and Keveyis; Xeris has great potential for 2022.
Upcoming Catalysts (Xeris)
Since many people ask about upcoming catalysts, I’ve decided to put together a few things that are on the horizon. A lot of the information can be found in the ER transcripts, but I know there are a lot of lazy investors who will never read an ER transcript so I’ll do my best to…
J.P. Morgan Healthcare Conference 2023 Transcript
Transcription may have some errors – apologize in advance Paul Edick – I would remind everyone to pay attention to our forward looking statements. Investing is always a risk. We’ll start out with an overview of the company. Xeris has a very diversified revenue base. We have three marketed assets, all growing record level. I’ll…
Q1 2022 Earning Call Audio & Transcription
Transcription is computer automated and may not be 100% accurate, but until Seeking Alpha provides their transcript, this is better than nothing. Once Seeking Alpha provides the call transcript, this automated transcription will be removed. Updated with Seeking Alpha transcript: Source Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2022 Earnings Conference Call May 11, 2022 8:30…
Q4 2021 Earning Call Audio & Transcription
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Allison Wey – SVP, IR and Corporate Communications Paul Edick – Chairman and CEO Steve Pieper – CFO Conference Call Participants Roanna Ruiz – SVB Leerink Vamil Divan – Mizuho Securities David Amsellem – Piper Sandler Operator Hello everyone….
Fireside Chat with Paul Edick – Xeris Biopharma – $XERS
Fireside chat with Paul Edick – CEO of Xeris Biopharma – $XERS
Ask A Question
Get Help From Shareholders
Ask and learn more from the XerisDD community about Financials, Products, Leadership, General, and Competition. Or select "Ask Allison" for the category, and we will ask Allison Wey, Xeris Pharma's SVP of Investor Relations & Corporate Communications.
Answer Questions
